Targeting the unmet global medical need caused by Gram-negative 'superbugs': from antibiotic discovery to novel therapeutic strategies

针对革兰氏阴性“超级细菌”引起的未满足的全球医疗需求：从抗生素发现到新的治疗策略

• 批准号: nhmrc : 1063069
• 负责人: Prof Jian Li
• 金额: $ 46.49万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Research Fellowships
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-unmet-global-therapeutic-strategies/455036
• 关键词: Targeting; unmet; global; medical; need

Bacterial ‘superbugs’ present a significant global medical challenge. ‘Old’ polymyxins are the only antibiotics against Gram-negative ‘superbugs’ but with limited pharmacological information available. In the next 5 years, as a pharmacologist I will continue re-developing polymyxins and discovering novel antibiotics against these problematic bacteria. My research targets the “Bad Bugs, No Drugs” disaster highlighted by the Infectious Diseases Society of America and the World Health Organization.

细菌“超级细菌”是一个重大的全球医学挑战。“老”多粘菌素是唯一针对革兰氏阴性“超级细菌”的抗生素，但可用的药理学信息有限。在接下来的5年里，作为一名药理学家，我将继续重新开发多粘菌素，并发现针对这些问题细菌的新型抗生素。我的研究目标是美国传染病协会和世界卫生组织强调的“坏虫子，没有药物”灾难。